Cargando…

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial

Background: The Easyhaler(®) device-metered dry powder inhaler containing Salmeterol and Fluticasone propionate (S/F) has been developed for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD). We report two studies which evaluated the in vitro flow rate dependence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jõgi, Rain, Lähelmä, Satu, Vahteristo, Mikko, Happonen, Anita, Haikarainen, Jussi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477585/ https://www.ncbi.nlm.nih.gov/pubmed/30300557 http://dx.doi.org/10.1089/jamp.2018.1463

Ejemplares similares

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects
por: Kirjavainen, Merja, et al.
Publicado: (2018)

Consistent Dosing Through the Salmeterol–Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime
por: Turpeinen, Anni, et al.
Publicado: (2021)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Dose uniformity of budesonide Easyhaler® under simulated real-life conditions and with low inspiration flow rates
por: Haikarainen, Jussi, et al.
Publicado: (2017)

Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler
por: Lähelmä, Satu, et al.
Publicado: (2015)

A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler(®) in routine clinical practice
por: Vinge, Ines, et al.
Publicado: (2021)

Patients with asthma or chronic obstructive pulmonary disease (COPD) can generate sufficient inspiratory flows via Easyhaler(®) dry powder inhaler: a pooled analysis of two randomized controlled trials
por: Malmberg, L. Pekka, et al.
Publicado: (2021)

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
por: Haughie, Scott, et al.
Publicado: (2020)

Effectiveness and Treatment Compliance of Salmeterol–Fluticasone Easyhaler(®) Among Patients with Asthma, COPD, or Asthma–COPD Overlap Syndrome: Real-World Study Findings
por: Tamási, Lilla, et al.
Publicado: (2022)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
por: Yasui, Hideki, et al.
Publicado: (2018)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial
por: Chen, Rixin, et al.
Publicado: (2010)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus
por: Cooper, Andrew, et al.
Publicado: (2020)

Novel Fluticasone Propionate and Salmeterol Fixed-Dose Combination Nano-Encapsulated Particles Using Polyamide Based on L-Lysine
por: Alyami, Mohammad H., et al.
Publicado: (2022)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
por: Ainali, Nina Maria, et al.
Publicado: (2020)

Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD
por: Jõgi, Rain, et al.
Publicado: (2021)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

Degradation rates and products of fluticasone propionate in alkaline solutions
por: Tokumura, Tadakazu, et al.
Publicado: (2017)

Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?
por: Akamatsu, Keiichiro, et al.
Publicado: (2011)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
por: Stanford, Richard H, et al.
Publicado: (2012)

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol
por: Pitrez, Paulo Marcio, et al.
Publicado: (2023)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
por: Woodcock, Ashley, et al.
Publicado: (2013)

Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2016)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

Step-down therapy in well-controlled asthmatic patients using salmeterol xinafoate/fluticasone propionate combination therapy
por: Horiuchi, Kazuya, et al.
Publicado: (2016)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

No dose effect observed with chronic fluticasone propionate on growth velocity in children
por: Lee, Laurie A., et al.
Publicado: (2020)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study
por: Roche, Nicolas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2qdk1jv1f6o1s6dap6j9un84am